Abstract: Antibiotic agents conjugated to a guanidinium-rich molecular transporter (GR-MoTr) are provided. The drug conjugates show surprising increases in efficacy compared to the unconjugated drug in difficult-to-treat bacterial infections including biofilms, stationary and persister cells, and multi-drug resistant bacteria, as well as intracellular bacteria.

Abstract: The design, synthesis, and biological evaluation of a new family of highly effective conjugate compounds, including dendrimeric moieties and branched structures, are described. Pharmaceutical compositions including the subject dendrimeric conjugates and methods of using the same are also provided. Methods of using the subject dendrimeric conjugates include delivering a cargo moiety conjugated to the dendrimeric moieties and branched structures to a cell under suitable conditions. In certain embodiments, the cell is a bacterial cell population, and the subject compounds reduce the bacterial cell population. In certain embodiments of the methods, the subject compound is capable of eradicating one or more of Gram-positive bacteria, mycobacteria, and Gram-negative bacteria. In certain embodiments of the methods, the subject compound is capable of eradicating bacterial biofilms. Methods of using the subject dendrimeric conjugates include treating a subject for a disease or condition.

Abstract: Phosphoethanolamine cellulose and methods of making and using it are disclosed. In particular, the invention relates to a method of producing a phosphoethanolamine cellulose biosynthetically using a BcsG phosphoethanolamine transferase for cellulose modification. Recombinant constructs encoding BcsG are described, including constructs encoding BcsG by itself or in combination with BcsE and BcsF, which increase the extent of cellulose modification and the amount of modified cellulose produced. Production of phosphoethanolamine cellulose in cell culture and derivatization of phosphoethanolamine cellulose are also described.

Abstract: Phosphoethanolamine cellulose and methods of making and using it are disclosed. In particular, the invention relates to a method of producing a phosphoethanolamine cellulose biosynthetically using a BcsG phosphoethanolamine transferase for cellulose modification. Recombinant constructs encoding BcsG are described, including constructs encoding BcsG by itself or in combination with BcsE and BcsF, which increase the extent of cellulose modification and the amount of modified cellulose produced. Production of phosphoethanolamine cellulose in cell culture and derivatization of phosphoethanolamine cellulose are also described.

Abstract: Phosphoethanolamine cellulose and methods of making and using it are disclosed. In particular, the invention relates to a method of producing a phosphoethanolamine cellulose biosynthetically using a BcsG phosphoethanolamine transferase for cellulose modification. Recombinant constructs encoding BcsG are described, including constructs encoding BcsG by itself or in combination with BcsE and BcsF, which increase the extent of cellulose modification and the amount of modified cellulose produced. Production of phosphoethanolamine cellulose in cell culture and derivatization of phosphoethanolamine cellulose are also described.

Abstract: Compositions and methods for the dissolution of a microbial biofilm are provided, where the method comprises contacting a microbiofilm with an effective dose of a curcumin derivative as a biofilm inhibitor. In some embodiments the curcumin derivative is dimethoxycurcumin. In some embodiments the biofilm comprises E. coli, e.g. including uropathogenic E. coli. The biofilm can be present in vitro or in vivo. The biofilm inhibitor may be administered alone, or in combination with bacteriocidal agents.

Abstract: Compositions and methods for the dissolution of a microbial biofilm are provided, where the method comprises contacting a microbiofilm with an effective dose of a curcumin derivative as a biofilm inhibitor. In some embodiments the curcumin derivative is dimethoxycurcumin. In some embodiments the biofilm comprises E. coli, e.g. including uropathogenic E. coli. The biofilm can be present in vitro or in vivo. The biofilm inhibitor may be administered alone, or in combination with bacteriocidal agents.

Abstract: Compositions and methods for the dissolution of a microbial biofilm are provided, where the method comprises contacting a microbiofilm with an effective dose of a curcumin derivative as a biofilm inhibitor. In some embodiments the curcumin derivative is dimethoxycurcumin. In some embodiments the biofilm comprises E. coli, e.g. including uropathogenic E. coli. The biofilm can be present in vitro or in vivo. The biofilm inhibitor may be administered alone, or in combination with bacteriocidal agents.